Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alto Neuroscience Inc (ANRO)

Alto Neuroscience Inc (ANRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 885,543
  • Shares Outstanding, K 31,946
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,240 K
  • EBIT $ -66 M
  • EBITDA $ -66 M
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.36

Options Overview Details

View History
  • Implied Volatility 111.40% (+8.53%)
  • Historical Volatility 83.52%
  • IV Percentile 9%
  • IV Rank 4.16%
  • IV High 756.33% on 05/16/25
  • IV Low 83.38% on 05/20/25
  • Expected Move (DTE 26) 1.02 (3.68%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 29
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 5,881
  • Open Int (30-Day) 5,380
  • Expected Range 26.70 to 28.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.56
  • Number of Estimates 5
  • High Estimate $-0.48
  • Low Estimate $-0.63
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) -5.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.41 +42.79%
on 03/24/26
28.11 -1.39%
on 04/17/26
+5.36 (+23.97%)
since 03/17/26
3-Month
13.91 +99.25%
on 02/06/26
28.11 -1.39%
on 04/17/26
+10.55 (+61.44%)
since 01/16/26
52-Week
2.12 +1,207.55%
on 05/07/25
28.11 -1.39%
on 04/17/26
+25.46 (+1,126.55%)
since 04/17/25

Most Recent Stories

More News
Stocks Recover on Hopes Strait of Hormuz Could Soon Reopen

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.11%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.11%. June E-mini...

ALK : 45.40 (+10.33%)
APO : 124.62 (+3.15%)
UAL : 101.80 (+7.12%)
ARES : 117.78 (+1.34%)
CARR : 61.32 (+2.70%)
$IUXX : 26,672.43 (+1.29%)
ZNM26 : 111-230s (+0.45%)
MTDR : 55.60 (-5.60%)
TSLA : 400.62 (+3.01%)
ESM26 : 7,161.50s (+1.19%)
NCLH : 20.99 (+4.79%)
BX : 129.08 (+0.74%)
Stocks Pare Losses on Hormuz Report

The S&P 500 Index ($SPX ) (SPY ) today is down -0.06%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.20%. June E-mini S&P futures...

ALK : 45.40 (+10.33%)
AMAT : 396.94 (+1.81%)
UAL : 101.80 (+7.12%)
MPC : 213.69 (-5.55%)
CVX : 183.99 (-2.21%)
$IUXX : 26,672.43 (+1.29%)
ASML : 1,459.80 (+3.47%)
ZNM26 : 111-230s (+0.45%)
OXY : 53.79 (-5.42%)
MTDR : 55.60 (-5.60%)
TSLA : 400.62 (+3.01%)
ESM26 : 7,161.50s (+1.19%)
Stocks Sink as President Trump Signals Iran War Will Drag On

The S&P 500 Index ($SPX ) (SPY ) today is down -1.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. June E-mini S&P futures...

ALK : 45.40 (+10.33%)
APO : 124.62 (+3.15%)
GOOGL : 341.68 (+1.68%)
ARES : 117.78 (+1.34%)
AAPL : 270.23 (+2.59%)
SNDK : 920.99 (+0.17%)
HL : 19.54 (+2.25%)
CDE : 20.38 (+4.46%)
OXY : 53.79 (-5.42%)
TSLA : 400.62 (+3.01%)
FANG : 180.27 (-3.42%)
STX : 547.75 (+3.00%)
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052)...

ANRO : 27.72 (+6.37%)
Alto Neuroscience Announces $120 Million Private Placement Financing

– Financing led by Commodore Capital with participation from new and existing biotech focused investors – –  Alto expects to use the proceeds of the financing to...

ANRO : 27.72 (+6.37%)
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – ...

ANRO : 27.72 (+6.37%)
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 27.72 (+6.37%)
Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

ANRO : 27.72 (+6.37%)
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the...

ANRO : 27.72 (+6.37%)
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

– The review provides strong scientific rationale to support Alto’s drug development approach leveraging its Precision Psychiatry Platform –

ANRO : 27.72 (+6.37%)

Business Summary

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

See More

Key Turning Points

3rd Resistance Point 30.92
2nd Resistance Point 29.52
1st Resistance Point 28.62
Last Price 27.72
1st Support Level 26.31
2nd Support Level 24.91
3rd Support Level 24.01

See More

52-Week High 28.11
Last Price 27.72
Fibonacci 61.8% 18.18
Fibonacci 50% 15.11
Fibonacci 38.2% 12.05
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.